Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Biomedical has entered into a license agreement with Advanced BioScience Laboratories, so that ABL may provide advanced electroporation delivery of DNA vaccines for its research uses.
Subscribe to our email newsletter
The license will permit Advanced BioScience Laboratories (ABL), based in Kensington, Maryland, to conduct certain internal research on DNA vaccines delivered using electroporation and to offer electroporation delivery of DNA vaccines as a service for its research customers. Inovio will receive a royalty on such services.
Avtar Dhillon, president and CEO of Inovio, said: “We believe this license may help enable the early development of a number of vaccines designed to elicit strong T-cell responses, which are thought to be needed to control a number of chronic infectious diseases, such as HIV and cancer.”